These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 15748838)

  • 1. Courting a cure for fragile X.
    Dölen G; Bear MF
    Neuron; 2005 Mar; 45(5):642-4. PubMed ID: 15748838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological rescue of synaptic plasticity, courtship behavior, and mushroom body defects in a Drosophila model of fragile X syndrome.
    McBride SM; Choi CH; Wang Y; Liebelt D; Braunstein E; Ferreiro D; Sehgal A; Siwicki KK; Dockendorff TC; Nguyen HT; McDonald TV; Jongens TA
    Neuron; 2005 Mar; 45(5):753-64. PubMed ID: 15748850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanism-based approaches to treating fragile X.
    Dölen G; Carpenter RL; Ocain TD; Bear MF
    Pharmacol Ther; 2010 Jul; 127(1):78-93. PubMed ID: 20303363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomedical research. A fix for fragile X syndrome?
    Miller G
    Science; 2006 Apr; 312(5773):521. PubMed ID: 16645065
    [No Abstract]   [Full Text] [Related]  

  • 5. Metabotropic glutamate receptors and fragile x mental retardation protein: partners in translational regulation at the synapse.
    Ronesi JA; Huber KM
    Sci Signal; 2008 Feb; 1(5):pe6. PubMed ID: 18272470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological reversal of synaptic plasticity deficits in the mouse model of fragile X syndrome by group II mGluR antagonist or lithium treatment.
    Choi CH; Schoenfeld BP; Bell AJ; Hinchey P; Kollaros M; Gertner MJ; Woo NH; Tranfaglia MR; Bear MF; Zukin RS; McDonald TV; Jongens TA; McBride SM
    Brain Res; 2011 Mar; 1380():106-19. PubMed ID: 21078304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role for metabotropic glutamate receptor 5 (mGluR5) in the pathogenesis of fragile X syndrome.
    Dölen G; Bear MF
    J Physiol; 2008 Mar; 586(6):1503-8. PubMed ID: 18202092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabotropic receptor-dependent long-term depression persists in the absence of protein synthesis in the mouse model of fragile X syndrome.
    Nosyreva ED; Huber KM
    J Neurophysiol; 2006 May; 95(5):3291-5. PubMed ID: 16452252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential therapeutic interventions for fragile X syndrome.
    Levenga J; de Vrij FM; Oostra BA; Willemsen R
    Trends Mol Med; 2010 Nov; 16(11):516-27. PubMed ID: 20864408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fragile X Syndrome and Alzheimer's Disease: Another story about APP and beta-amyloid.
    Malter JS; Ray BC; Westmark PR; Westmark CJ
    Curr Alzheimer Res; 2010 May; 7(3):200-6. PubMed ID: 20088809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fragile X syndrome: an update on developing treatment modalities.
    Healy A; Rush R; Ocain T
    ACS Chem Neurosci; 2011 Aug; 2(8):402-10. PubMed ID: 22860169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic strategies in fragile X syndrome: dysregulated mGluR signaling and beyond.
    Gross C; Berry-Kravis EM; Bassell GJ
    Neuropsychopharmacology; 2012 Jan; 37(1):178-95. PubMed ID: 21796106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional rescue of excitatory synaptic transmission in the developing hippocampus in Fmr1-KO mouse.
    Meredith RM; de Jong R; Mansvelder HD
    Neurobiol Dis; 2011 Jan; 41(1):104-10. PubMed ID: 20817093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic implications of the mGluR theory of fragile X mental retardation.
    Bear MF
    Genes Brain Behav; 2005 Aug; 4(6):393-8. PubMed ID: 16098137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suppression of two major Fragile X Syndrome mouse model phenotypes by the mGluR5 antagonist MPEP.
    Yan QJ; Rammal M; Tranfaglia M; Bauchwitz RP
    Neuropharmacology; 2005 Dec; 49(7):1053-66. PubMed ID: 16054174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fragile X mental retardation protein deficiency leads to excessive mGluR5-dependent internalization of AMPA receptors.
    Nakamoto M; Nalavadi V; Epstein MP; Narayanan U; Bassell GJ; Warren ST
    Proc Natl Acad Sci U S A; 2007 Sep; 104(39):15537-42. PubMed ID: 17881561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The mGluR theory of fragile X mental retardation.
    Bear MF; Huber KM; Warren ST
    Trends Neurosci; 2004 Jul; 27(7):370-7. PubMed ID: 15219735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fragile X syndrome neurobiology translates into rational therapy.
    Braat S; Kooy RF
    Drug Discov Today; 2014 Apr; 19(4):510-9. PubMed ID: 24508819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Absence of metabotropic glutamate receptor-mediated plasticity in the neocortex of fragile X mice.
    Wilson BM; Cox CL
    Proc Natl Acad Sci U S A; 2007 Feb; 104(7):2454-9. PubMed ID: 17287348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reducing glutamate signaling pays off in fragile X.
    Bassell GJ; Gross C
    Nat Med; 2008 Mar; 14(3):249-50. PubMed ID: 18323845
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.